NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$92.58 +3.19 (+3.57 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$89.39
Today's Range$88.84 - $92.77
52-Week Range$37.13 - $127.77
Volume287,600 shs
Average Volume238,260 shs
Market Capitalization$1.82 billion
P/E Ratio100.86
Dividend YieldN/A
Beta0.92
Enanta Pharmaceuticals logoEnanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800

Debt

Debt-to-Equity RatioN/A
Current Ratio24.24
Quick Ratio24.24

Price-To-Earnings

Trailing P/E Ratio100.86
Forward P/E Ratio26.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$102.81 million
Price / Sales17.45
Cash Flow$1.0602 per share
Price / Cash87.32
Book Value$15.80 per share
Price / Book5.86

Profitability

EPS (Most Recent Fiscal Year)$0.91
Net Income$17.71 million
Net Margins37.63%
Return on Equity25.84%
Return on Assets24.22%

Miscellaneous

Employees89
Outstanding Shares19,380,000
Market Cap$1.82 billion

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported $0.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.98 by $0.01. The biotechnology company earned $57.26 million during the quarter, compared to analysts' expectations of $56.59 million. Enanta Pharmaceuticals had a net margin of 37.63% and a return on equity of 25.84%. View Enanta Pharmaceuticals' Earnings History.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 19th 2018. View Earnings Estimates for Enanta Pharmaceuticals.

What price target have analysts set for ENTA?

6 brokerages have issued 12-month price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $80.00 to $133.00. On average, they expect Enanta Pharmaceuticals' share price to reach $108.25 in the next twelve months. This suggests a possible upside of 16.9% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

What is the consensus analysts' recommendation for Enanta Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Who are some of Enanta Pharmaceuticals' key competitors?

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the folowing people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 62)
  • Dr. Yat Sun Or, Sr. VP-R&D and Chief Scientific Officer (Age 66)
  • Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 52)
  • Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 63)
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 64)

Has Enanta Pharmaceuticals been receiving favorable news coverage?

Headlines about ENTA stock have been trending positive on Saturday, according to Accern Sentiment. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 0.27 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.42 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Enanta Pharmaceuticals.

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.63%), Renaissance Technologies LLC (4.56%), First Manhattan Co. (2.95%), Acadian Asset Management LLC (1.98%), Bank of New York Mellon Corp (1.28%) and Janus Henderson Group PLC (0.66%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

Which major investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, First Manhattan Co., Eqis Capital Management Inc., State of Wisconsin Investment Board, United Services Automobile Association, Alps Advisors Inc., Alps Advisors Inc. and California Public Employees Retirement System. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda and Paul J Mellett. View Insider Buying and Selling for Enanta Pharmaceuticals.

Which major investors are buying Enanta Pharmaceuticals stock?

ENTA stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, First Trust Advisors LP, BlackRock Inc., Federated Investors Inc. PA, Russell Investments Group Ltd., Renaissance Technologies LLC, American Century Companies Inc. and TD Asset Management Inc.. View Insider Buying and Selling for Enanta Pharmaceuticals.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $92.58.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $1.82 billion and generates $102.81 million in revenue each year. The biotechnology company earns $17.71 million in net income (profit) each year or $0.91 on an earnings per share basis. Enanta Pharmaceuticals employs 89 workers across the globe.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]


MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  437
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.